Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global current systems in the magnetosphere of Mercury.

Nature communications·2026
Same author

Response: Codeine in Breast Milk: Minimal Transfer, Still Risky for Neonates.

Paediatric anaesthesia·2026
Same author

Codeine and Metabolite Concentrations in the Breastfed Neonate.

Paediatric anaesthesia·2026
Same author

Milk Fasting Times and Aspiration in Infants.

Paediatric anaesthesia·2026
Same author

Whole blood transcriptomics reveals sepsis mortality-associated changes in neutrophil degranulation.

American journal of respiratory cell and molecular biology·2026
Same author

Individualising drug therapy in intensive care.

Anaesthesia and intensive care·2026

Related Experiment Video

Updated: Jun 4, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Tips and traps analyzing pediatric PK data.

Brian J Anderson1, Nick H G Holford

  • 1Department of Anaesthesiology, University of Auckland School of Medicine, Auckland, New Zealand. briana@adhb.govt.nz

Paediatric Anaesthesia
|February 16, 2011
PubMed
Summary
This summary is machine-generated.

Sophisticated pharmacokinetic (PK) and pharmacodynamic (PD) modeling in developmental pharmacology has pitfalls. This review highlights issues in pediatric anesthetic drug dosing, including birth effects, obesity, physiology, disease, and metabolites, offering solutions.

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Related Experiment Videos

Last Updated: Jun 4, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Area of Science:

  • Developmental Pharmacology
  • Anesthesia
  • Pharmacometrics

Background:

  • Pharmacokinetic (PK) and pharmacodynamic (PD) modeling is crucial in developmental pharmacology for anesthesia.
  • Increasingly complex modeling techniques present potential pitfalls for researchers and clinicians.
  • Standard covariates like size and age are well-studied, but other factors are often overlooked.

Purpose of the Study:

  • To identify and discuss common pitfalls in PK/PD modeling for pediatric anesthesia.
  • To highlight areas where current modeling approaches may be insufficient or misleading.
  • To propose strategies for addressing these modeling challenges.

Main Methods:

  • Literature review focusing on PK/PD modeling in pediatric anesthesiology.
  • Critical analysis of existing modeling practices and their limitations.
  • Identification of under-investigated areas in developmental drug modeling.

Main Results:

  • Poor documentation of clearance maturation post-birth.
  • Limited investigation of drug dosing in obese pediatric populations.
  • Inadequate portrayal of physiological changes' pharmacologic impact.
  • Underestimation of disease progression's effect on drug response.
  • Poor illustration of metabolites' influence on drug effects.

Conclusions:

  • Awareness of these PK/PD modeling pitfalls is essential for accurate pediatric anesthetic drug development and application.
  • Further research is needed to refine models considering factors like birth, obesity, physiology, disease, and metabolites.
  • Implementing suggested strategies can improve the reliability and clinical utility of PK/PD models in pediatric anesthesia.